<DOC>
	<DOCNO>NCT01102712</DOCNO>
	<brief_summary>To establish confirm safety clinical utility BTVA apply unilaterally lung volume reduction patient upper lobe predominate heterogeneous severe emphysema .</brief_summary>
	<brief_title>Bronchoscopic Thermal Vapor Ablation ( BTVA ) Lung Volume Reduction</brief_title>
	<detailed_description>All subject meet eligibility criterion provide write informed consent enrol . Up 3 segment either right leave upper lobe treat vapor dose 10 calorie per gram lung tissue ( 10 cal/g ) . Targeted lobe treatment base lobar disease severity .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>1 . Age : &gt; 40 ≤ 75 year old 2 . Diagnosis heterogeneous emphysema upper lobe predominance 3 . FEV1 &lt; 45 % predict 4 . TLC &gt; 100 % predict 5 . RV &gt; 150 % predict 6 . 6minute walk test &gt; 140 meter 7. mMRC ≥ 2 ( mMRC ) 8 . Nonsmoking 3 month 9 . Optimized medical management complete pulmonary rehabilitation 1 . Known α1antitrypsin deficiency 2 . BMI &lt; 15 kg/m2 &gt; 35 kg / m2 3 . History pneumothorax within previous 18 month 4 . History heart / lung transplant , lung volume reduction surgery ( LVRS ) , median sternotomy , bullectomy , and/or lobectomy 5 . Respiratory infection recur COPD exacerbation &gt; 3 hospitalization past 12 month active infection 6 . History ( EF ) ≤ 40 % ; Stroke ; Unstable Myocardial Ischemia ; FEV1 &lt; 15 % predict ; DLCO &lt; 20 % predict ; pulmonary hypertension ; indwell pacemaker implantable cardiac defibrillator ( ICD ) ; pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Emphysema</keyword>
	<keyword>COPD</keyword>
	<keyword>Lung Volume Reduction</keyword>
	<keyword>BTVA</keyword>
</DOC>